New tests to track liver health during radiation for liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests new blood tests and MRI scans to see how well your liver works during radiation therapy for liver cancer. It may help doctors better plan treatment and monitor your liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have liver cancer (hepatocellular carcinoma, cholangiocarcinoma) or cancer that spread to the liver.
- You need to be able to have an MRI (no metal implants, no claustrophobia, and can lie still).
- You are not pregnant or breastfeeding.
- For the extra HepQuant test (first 20 participants): you must be willing to fast for 5 hours and possibly delay some medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial studies a new strategy for hepatocellular carcinoma (a type of liver cancer) in people who are planned to receive TACE, a procedure that delivers treatment through the liver’s blood supply. It aims to test whether targeting a specific cell survival process can improve how well the treatment works and is tolerated.
This trial is for people with liver cancer (hepatocellular carcinoma) who are about to receive a type of internal radiation therapy called TARE (also known as radioembolization). Researchers want to learn more about how the cancer responds to this treatment using scans and biopsies. You might be a good fit if you have not had any prior treatment for your liver cancer.
This trial studies a combination approach—special, image-guided radiation and liver procedures—for liver cancer patients who cannot have surgery. It may help shrink tumors while protecting liver function by using planned, targeted treatment.
This trial studies how radiation therapy affects the immune system and outcomes in people with liver cancer. It may help doctors understand better ways to treat the disease.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests whether special “4D” MRI scans can improve precision radiation planning for people with lung or liver cancer. You may get MRI scan data to better account for tumor movement, alongside your usual radiation treatment.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.